Samsung Biologics Shares Rise on Growth Momentum – What to Watch Samsung Biologics shows strong growth in revenue and operating profit, supported by M&A expansion like PolyPeptide, but key risk is renewed production disruptions and integration costs. 2026년 07월 22일 English
Samsung Biologics Profit Improves Yet Stock Undervalued: Why Samsung Biologics is rated Buy as strong margins and revenue growth persist despite labor disruption fears, leaving the stock below the average analyst target. 2026년 07월 07일 English
Samsung Biologics Earnings Jump 25.8% YoY: Key Risks Samsung Biologics is rated Buy with strong growth and margins, but stock risk is driven by labor and legal disputes that could disrupt production, raise costs, and hurt future earnings. 2026년 06월 11일 English
Samsung Biologics Shares Rally on Strong Growth: Key Insights Samsung Biologics stays a Buy: despite labor, legal, and quality recall risks, 2026.03 revenue rose 25.8% YoY and operating profit 35.0% YoY, supporting margin resilience and upside. 2026년 06월 02일 English
Samsung Biologics Quarterly Profit Jumps – Key Margin Insights Samsung Biologics is a Buy: operating profit rose 39.7% despite revenue decline, but labor disputes may create volatility until next-quarter results confirm stabilization. 2026년 05월 21일 English
Samsung Biologics Labor Unrest Fears Ease: Profit Resilience Samsung Biologics is rated Buy: labor unrest threatens production, but latest results show operating profit and net income growth despite revenue collapse, suggesting the stock’s risk discount may be excessive. 2026년 05월 05일 English
